Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer
An Open, Multicenter, Randomized Controlled Clinical Study of Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
- Phase 3
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
female patients aged greater than or equal to 18 years and less than or equal to 75 years, meet one of the following:
- previous oophorectomy, or age ≥ 60 years;
- age < 60 years, natural postmenopausal status (defined as at least 12 consecutive months of spontaneous cessation of regular menstruation, and no other pathological or physiological causes), E2 and FSH in postmenopausal levels;
- premenopausal or perimenopausal female patients, must be willing to receive LHRH agonist therapy during the study;
- all patients were confirmed by histopathology as estrogen receptor (ER) positive (> 10%), HER2 receptor negative.Follow the 2018 version of ASCO-CAP HER2-negative interpretation guideline criteria;
- tumor stage II-III meeting the AJCC 8th version criteria, patients who have previously received 2 cycles of TE regimen chemotherapy, with disease evaluation of SD or PD;
- KPS score ≥ 70 points;
organ function level must meet the following requirements:
- bone marrow function ANC ≥ 1.5 × 109/L (14 without growth factors); PLT ≥ 100 × 109/L (7 without corrective treatment); Hb ≥ 100 g/L (7) without corrective treatment;
- liver and kidney function TBIL ≤ 1.5 × ULN; ALT and AST ≤ 3 × ULN; BUN and Cr ≤ 1.5 × ULN and creatinine clearance ≥ 50 mL/min (Cockcroft-Gault formula);
- able to undergo needle biopsy;
- voluntarily join this study, sign informed consent, have good compliance and are willing to cooperate with follow-up
Exclusion Criteria:
- received any form of anti-tumor therapy (chemotherapy, radiotherapy, molecular targeted therapy, endocrine therapy, etc.);
- received any other anti-tumor therapy at the same time;
- breast cancer, inflammatory breast cancer or occult breast cancer;
- stage IV breast cancer;
- breast cancer without histopathological diagnosis;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Chidamide group
Chidamide combined with exemestane (+/- goserelin)
|
Chidamide combined with exemestane (+/- goserelin)
|
|
Active Comparator: chemotherapy group
Chemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician)
|
Chemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
ORR
Time Frame: Up to approximately 48 months
|
Up to approximately 48 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
pCR:Upon completion of neoadjuvant therapy and surgery, there was no residual invasive carcinoma present in the pathologic assessment of the resected breast cancer samples stained with hematoxylin and eosin and all ipsilateral lymph node samples.
Time Frame: Up to approximately 48 months
|
Up to approximately 48 months
|
|
Residual tumor burden (RCB) classification
Time Frame: Up to approximately 48 months
|
Up to approximately 48 months
|
|
Total breast pathological complete remission rate (bpCR)
Time Frame: Up to approximately 48 months
|
Up to approximately 48 months
|
|
PEPI classification
Time Frame: Up to approximately 48 months
|
Up to approximately 48 months
|
|
Breast-conserving rate
Time Frame: Up to approximately 48 months
|
Up to approximately 48 months
|
|
patient-reported outcome(PRO):evaluate daily functioning and health outcomes from the patient's perspective by HRQOL
Time Frame: Up to approximately 48 months
|
Up to approximately 48 months
|
|
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Time Frame: Up to approximately 48 months
|
Up to approximately 48 months
|
|
Number of participants with treatment-related serious adverse event as assessed by CTCAE v5.0
Time Frame: Up to approximately 48 months
|
Up to approximately 48 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antibiotics, Antineoplastic
- Hormone Antagonists
- Aromatase Inhibitors
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Docetaxel
- Epirubicin
- Goserelin
- Exemestane
Other Study ID Numbers
Other Study ID Numbers
- MUKDEN5
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.